Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Frequently asked questions
What sector does TECX (TECX) operate in?
TECX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is TECX (TECX) current stock price?
As of the latest data, TECX stock price is $19.95, with a previous close of $20.07. TECX lost -$0.12 in the last trading session, representing a -0.6% loss.
What is TECX (TECX) current market capitalization?
TECX market cap is approximately 390.01 million.
What is TECX (TECX) Earnings Per Share (EPS)?
The trailing EPS is -$4.57, and the forward EPS is -$4.76.
What is TECX (TECX) EBITDA?
TECX EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -21.92 million.
Does TECX (TECX) pay dividends?
No. TECX does not pay a dividend.
When is TECX (TECX) next earnings report?
TECX is expected to release its next earnings report on September 30, 2026.
What is TECX (TECX) beta (volatility) score?
TECX has a beta of 0.377, indicating lower volatility than the overall market.